Department of Anatomy and Cell Biology, McGill University, Montreal H3G 1Y6, Canada.
Integrated Program in Neuroscience, McGill University, Montreal H3G 1Y6, Canada.
Endocrinology. 2022 Aug 1;163(8). doi: 10.1210/endocr/bqac092.
Loss of function mutations in IGSF1/Igsf1 cause central hypothyroidism. Igsf1 knockout mice have reduced pituitary thyrotropin-releasing hormone receptor, Trhr, expression, perhaps contributing to the phenotype. Because thyroid hormones negatively regulate Trhr, we hypothesized that IGSF1 might affect thyroid hormone availability in pituitary thyrotropes. Consistent with this idea, IGSF1 coimmunoprecipitated with the thyroid hormone transporter monocarboxylate transporter 8 (MCT8) in transfected cells. This association was impaired with IGSF1 bearing patient-derived mutations. Wild-type IGSF1 did not, however, alter MCT8-mediated thyroid hormone import into heterologous cells. IGSF1 and MCT8 are both expressed in the apical membrane of the choroid plexus. However, MCT8 protein levels and localization in the choroid plexus were unaltered in Igsf1 knockout mice, ruling out a necessary chaperone function for IGSF1. MCT8 expression was low in the pituitary and was similarly unaffected in Igsf1 knockouts. We next assessed whether IGSF1 affects thyroid hormone transport or action, by MCT8 or otherwise, in vivo. To this end, we treated hypothyroid wild-type and Igsf1 knockout mice with exogenous thyroid hormones. T4 and T3 inhibited TSH release and regulated pituitary and forebrain gene expression similarly in both genotypes. Interestingly, pituitary TSH beta subunit (Tshb) expression was consistently reduced in Igsf1 knockouts relative to wild-type regardless of experimental condition, whereas Trhr was more variably affected. Although IGSF1 and MCT8 can interact in heterologous cells, the physiological relevance of their association is not clear. Nevertheless, the results suggest that IGSF1 loss can impair TSH production independently of alterations in TRHR levels or thyroid hormone action.
IGSF1/Igsf1 的功能丧失突变导致中枢性甲状腺功能减退症。Igsf1 敲除小鼠的垂体促甲状腺素释放激素受体 Trhr 表达减少,这可能是其表型的原因。由于甲状腺激素负调节 Trhr,我们假设 IGSF1 可能会影响垂体促甲状腺细胞中的甲状腺激素可用性。与这一观点一致的是,IGSF1 在转染细胞中与甲状腺激素转运体单羧酸转运蛋白 8(MCT8)共免疫沉淀。这种关联在具有患者衍生突变的 IGSF1 中受损。然而,野生型 IGSF1 并未改变 MCT8 介导的甲状腺激素进入异源细胞的摄取。IGSF1 和 MCT8 均在脉络丛的顶膜中表达。然而,在 Igsf1 敲除小鼠中,MCT8 蛋白水平和在脉络丛中的定位没有改变,排除了 IGSF1 作为必需伴侣的功能。MCT8 在垂体中的表达水平较低,在 Igsf1 敲除小鼠中也没有受到影响。我们接下来评估 IGSF1 是否通过 MCT8 或其他方式在体内影响甲状腺激素的转运或作用。为此,我们用外源性甲状腺激素治疗甲状腺功能减退的野生型和 Igsf1 敲除小鼠。T4 和 T3 以类似的方式抑制 TSH 释放并调节垂体和前脑基因表达,在两种基因型中均相似。有趣的是,无论实验条件如何,相对于野生型,IGSF1 敲除小鼠的垂体 TSHβ亚基(Tshb)表达始终降低,而 Trhr 的影响则更为多变。尽管 IGSF1 和 MCT8 可以在异源细胞中相互作用,但它们关联的生理相关性尚不清楚。尽管如此,结果表明 IGSF1 的缺失可以独立于 TRHR 水平或甲状腺激素作用的改变而损害 TSH 的产生。